Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts rate Autolus Therapeutics “Moderate Buy.” Of eight analysts, four recommend buying, two strongly recommend buying, one rates it a hold and one recommends selling; the average 12-month price target is $10.00.
• AUTL shares opened at $2.44 and were reported up 4.3%, near their 52-week high of $2.58. The company recently exceeded quarterly expectations, reporting a loss of $0.15 per share versus the $0.21 consensus loss and revenue of $45.69 million versus $38.56 million expected.
• Institutional investors own 72.83% of the stock. Recent activity included new positions from Alphabet and Syncona Portfolio, while Autolus continues developing programmed T-cell therapies, including its lead AUTO1 and AUTO3 CAR-T candidates.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $10.00.

AUTL has been the topic of several recent analyst reports. Wall Street Zen raised Autolus Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, August 16th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, August 3rd. Finally, Weiss Ratings raised Autolus Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, August 13th.

Autolus Therapeutics Trading Up 4.3%

Autolus Therapeutics stock opened at $2.44 on Wednesday. Autolus Therapeutics has a 52 week low of $1.17 and a 52 week high of $2.58. The company has a debt-to-equity ratio of 1.04, a quick ratio of 4.40 and a current ratio of 4.89. The firm has a market capitalization of $649.43 million, a price-to-earnings ratio of -2.30 and a beta of 2.07. The company has a 50 day moving average price of $1.76 and a 200 day moving average price of $1.62.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.06. The company had revenue of $45.69 million for the quarter, compared to the consensus estimate of $38.56 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. Research analysts forecast that Autolus Therapeutics will post -0.75 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Alphabet Inc. bought a new position in Autolus Therapeutics in the 2nd quarter worth $1,117,000. Syncona Portfolio Ltd acquired a new stake in Autolus Therapeutics during the second quarter worth about $26,625,152,000. Hennion & Walsh Asset Management Inc. grew its position in Autolus Therapeutics by 2.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company's stock worth $722,000 after buying an additional 11,197 shares in the last quarter. GAMMA Investing LLC increased its stake in Autolus Therapeutics by 115.6% during the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company's stock valued at $25,000 after acquiring an additional 8,309 shares during the period. Finally, Waverly Advisors LLC bought a new position in Autolus Therapeutics during the first quarter valued at about $37,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source